Insights

Axinn Viewpoints

Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights

Earlier this month, a federal district court denied the Outsourcing Facilities Association’s preliminary injunction motion, which sought to preclude FDA from taking enforcement action against compounded tirzepatide products.^[1]

Learn More

Axinn Viewpoints

Axinn Associates at the Antitrust Spring Meeting

During the Spring Meeting, Axinn associates attended thought leadership panels to capture key insights. Read their takeaways from the panels.

Learn More

Axinn Viewpoints

Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights

Earlier this month, a federal district court denied the Outsourcing Facilities Association’s preliminary injunction motion, which sought to preclude FDA from taking enforcement action against compounded tirzepatide products.^[1]

Learn More

Axinn Viewpoints

Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights

Earlier this month, a federal district court denied the Outsourcing Facilities Association’s preliminary injunction motion, which sought to preclude FDA from taking enforcement action against compounded tirzepatide products.^[1]

Learn More

Practices

Type

People

Most recent

2 results

February 25, 2025

Will the Supreme Court Upend the Jurisdictional Landscape?

Many defendants with no connection to the jurisdiction in which they are sued may assert a personal jurisdiction defense to avoid...

Axinn Viewpoints

Litigation & Trials

January 27, 2025

Litigation Partner Scott Eisman Joins Axinn in New York

Axinn, Veltrop & Harkrider LLP announced today that Scott Eisman has joined its litigation practice as a partner in the New York office.

News

Litigation & Trials

Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights

Axinn Associates at the Antitrust Spring Meeting

Brand Building and Buy-In: How a Strong Brand Can Drive Law Firm Growth

Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights

Axinn Associates at the Antitrust Spring Meeting

Brand Building and Buy-In: How a Strong Brand Can Drive Law Firm Growth

Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights

Insights

2 results

Events